#### Check for updates

#### **OPEN ACCESS**

EDITED BY Brian James Dlouhy, The University of Iowa, United States

REVIEWED BY Irina Oane, Bucharest University Emergency Hospital, Romania Massimo Mantegazza, UMR7275 Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), France

\*CORRESPONDENCE Henner Koch Mkoch@ukaachen.de

SPECIALTY SECTION This article was submitted to Epilepsy, a section of the journal Frontiers in Neurology

RECEIVED 09 September 2022 ACCEPTED 12 December 2022 PUBLISHED 06 January 2023

#### CITATION

Bauer J, Devinsky O, Rothermel M and Koch H (2023) Autonomic dysfunction in epilepsy mouse models with implications for SUDEP research. *Front. Neurol.* 13:1040648. doi: 10.3389/fneur.2022.1040648

#### COPYRIGHT

© 2023 Bauer, Devinsky, Rothermel and Koch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

### Autonomic dysfunction in epilepsy mouse models with implications for SUDEP research

Jennifer Bauer<sup>1,2</sup>, Orrin Devinsky<sup>3</sup>, Markus Rothermel<sup>2</sup> and Henner Koch<sup>1\*</sup>

<sup>1</sup>Department of Epileptology and Neurology, RWTH Aachen University, Aachen, Germany, <sup>2</sup>Institute for Physiology and Cell Biology, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany, <sup>3</sup>Departments of Neurology, Neurosurgery and Psychiatry, NYU Langone School of Medicine, New York, NY, United States

Epilepsy has a high prevalence and can severely impair quality of life and increase the risk of premature death. Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in drug-resistant epilepsy and most often results from respiratory and cardiac impairments due to brainstem dysfunction. Epileptic activity can spread widely, influencing neuronal activity in regions outside the epileptic network. The brainstem controls cardiorespiratory activity and arousal and reciprocally connects to cortical, diencephalic, and spinal cord areas. Epileptic activity can propagate trans-synaptically or via spreading depression (SD) to alter brainstem functions and cause cardiorespiratory dysfunction. The mechanisms by which seizures propagate to or otherwise impair brainstem function and trigger the cascading effects that cause SUDEP are poorly understood. We review insights from mouse models combined with new techniques to understand the pathophysiology of epilepsy and SUDEP. These techniques include in vivo, ex vivo, invasive and non-invasive methods in anesthetized and awake mice. Optogenetics combined with electrophysiological and optical manipulation and recording methods offer unique opportunities to study neuronal mechanisms under normal conditions, during and after non-fatal seizures, and in SUDEP. These combined approaches can advance our understanding of brainstem pathophysiology associated with seizures and SUDEP and may suggest strategies to prevent SUDEP.

KEYWORDS

epilepsy, SUDEP, brainstem, mouse models, cardiorespiratory activity

### **Epilepsy and SUDEP**

Epilepsy affects  $\sim 0.75\%$  of all people (1), or  $\sim 50$  million people worldwide, with an incidence of 4–10/1000 people/year. Epileptic seizures result from abnormal hypersynchronous neuronal activity (2, 3). Most seizures arise from both hemispheres simultaneously (generalized) or from restricted regions in one or both hemispheres but can propagate widely (focal) (4, 5). Anti-seizure medicines (ASMs) prevent seizures for  $\sim 67\%$  of patients, but many well-controlled patients experience cognitive and behavioral comorbid disorders and ASMs side effects. One-third of patients have drug-resistant epilepsy and often take multiple and high doses of ASMs with greater comorbidities, adverse effects, impairments of quality of life, and higher mortality (6–8).

Sudden unexpected death in epilepsy (SUDEP) is a witnessed or unwitnessed, non-drowning, and non-traumatic death in a person with epilepsy which often but not always follows a convulsive seizure. SUDEP excludes status epilepticus and cases where post-mortem examination or toxicology reveals another cause of death (9). SUDEP is the leading cause of death in drug-resistant epilepsy (DRE), with an incidence rate of 1-5 cases per 1000 patients per year (10, 11). SUDEP is the second leading neurological cause of lost years of life after stroke (12). Case-control studies reveal the following risk factors: generalized tonic-clonic seizures (GTCS) (any in the last year and further increased risk with  $\geq$  3/year), lack of adequate medication, nocturnal seizures, and lack of nocturnal supervision (13, 14). Many SUDEP cases are undetected or misclassified, suggesting the incidence is higher than reported (13, 15).

**SUDEPs** recorded The few on video with electroencephalographic and electrocardiographic data are biased toward more severe focal epilepsy cases admitted for presurgical evaluation with rapid ASMs reduction (16). By contrast, SUDEP affects the full spectrum of people with epilepsy (17), and results from epilepsy monitoring units cannot be generalized. The underlying mechanisms of SUDEP remain poorly defined. Most occur during sleep and follow convulsive seizures, with reduced brain activity and respiratory impairments commonly observed, although cardiac dysfunction can contribute (18-20). Postictal disruption of brainstem regulation of arousal, respiratory and cardiovascular functions is considered the common final pathway of death in SUDEP (9, 20-23). In animal models, arousal and cardiorespiratory dysfunctions can result from fast direct synaptic circuit mechanisms (24-27) and slower phenomenons like spreading depressions (SD) (28-31). How cortical seizure activity impairs brainstem functions postictally is a critical research issue. Understanding this pathophysiology will inform preventative and therapeutic strategies. We review potential mechanisms of seizure propagation and spread that might contribute to SUDEP, examine models used to study the mechanisms, and highlight advances in investigating complex network interaction in vivo in mouse models.

### Propagation of epileptic activity – the problem of a highly connected brain

This section reviews the following questions: how does epileptic activity spread to the brainstem? Is this a rare event, or common but usually compensated for (and if so, how)?

Rodent, primate, and human brains orchestrate multiple areas to optimally assess internal and external conditions and determine behavioral outputs. This requires high connectivity, precise coordination, and balance between interacting corticalsubcortical networks. During cortical seizures, affected areas are directly impacted by aberrant excitation and inhibition. In addition, areas beyond the epileptic network can be severely disturbed by ictal spread to resonating areas. The brainstem receives projections from cortical and subcortical brain areas (32-34). During and after seizures, these connections can alter brainstem activity and potentially impair arousal and cardiorespiratory functions and contribute to SUDEP (32, 34-36). Understanding why some cortical seizures propagate to other cortical and subcortical areas and how this disrupts brainstem activity is a major challenge in SUDEP research. The brain regions involved in epileptic circuits - cerebral cortex (37), hippocampus (38), amygdala (39, 40), and thalamus (41) - are directly and indirectly connected to the brainstem and exert powerful influences over it. The brainstem and more rostral cerebral regions share strong reciprocal connections, complicating our understanding. We review new techniques to study network interaction involved in SUDEP in epileptic mouse models.

# General concepts of the spreading of pathological activity

Epileptic seizures can be provoked by disrupting neuronal E/I balance by altering intrinsic properties, or by altering synaptic transmission and network stability causing hypersynchronous activity (42). The mechanisms underlying seizure propagation and termination are less well characterized. Focal seizures influence other brain areas via rapid axonal connections or spreading depression (SD), a slow propagating depolarization wave that inactivates neurons (25, 31, 35, 36). This slow ictal wavefront propagation corresponds to the gradual evolution of seizure symptoms, as in the Jacksonian sensory symptom march (43). The ictal wavefront may evoke a feedback loop to the seizure focus which triggers the clinical symptoms. Failure of feedforward inhibition supports epileptiform activity and seizure spread via this slow route in addition to classic synaptic pathways (44, 45). While SD contributes to symptoms of migraine and epilepsy, the mechanisms may be conserved or divergent (29, 46). The propagation rate of SD in migraine and epilepsy are similar, but their onset, duration, impacted brain regions and EEG changes can differ (47-50). Different SDs might exert distinct influences on brainstem function and SUDEP risk (29, 51). Debate persists whether this risk is primarily an ictal or post-ictal phenomenon. While the ictal seizure spreading into the brainstem might cause direct autonomic dysfunctions (36, 52, 53), the disturbance in the post-ictal period might substantially outlast the seizures. The post-ictal EEG suppression is viewed as a potential contributor but only a weak SUDEP predictor (54-56).

Mouse models of familial hemiplegic migraine with mutations in *Cacna1a* (57, 58), *Atp1a2* (59) and *Scn1a* (60, 61) show increased mortality. In mice with *Cacn1a* variants, brainstem SD elicited by seizures can be fatal (31). Brainstem SD may directly impair cardiorespiratory function (21, 30, 31, 35, 40). In focal seizures, SD with seizure propagation may be restricted to cortical regions in most instances. SDs were directly triggered by high neuronal activity of focally induced seizures and prevented by applying tetrodotoxin (TTX; a potent sodium channel inhibitor) (62). The authors postulate that SD is an innate mammalian mechanism to prevent seizure propagation and generalization, and to induce seizure termination (62). However, if SDs reach brainstem autonomic centers, severe cardiorespiratory dysfunction may follow (31, 63).

## Brain areas linked to autonomic control

Human studies used electrical stimulation or the time of seizure invasion to investigate cortical structures that alter breathing. These brain areas include the amygdala (32, 36, 64), the hippocampus head and body, anterior parahippocampal gyrus, and antero-mesial fusiform gyrus (65, 66). A pediatric study found apneas and seizure spread to the amygdala were strongly correlated (67), an adult study failed to replicate this (64). Electrical stimulation to the insula and left cingulate gyrus decreased cardiac output and induced cardiac asystole in epilepsy patients without effects on breathing (68, 69). However, electrical activation cannot precisely target specific neurons and circuits. Further, cortical and subcortical electrode coverage is limited. So the invasion of ictal activity to a region (e.g., amygdala) may be accompanied by spread to areas that were not sampled (e.g., hypothalamus, anterior cingulate, and orbitofrontal cortices). Also, correlating seizure invasion to apneas might reveal only some parts of the network involved in autonomic dysfunction. In animals and humans, physiological changes in subcortical areas (e.g., locus coeruleus) alter breathing (27, 70).


In addition to seizure invasion of cortical areas, altered connectivity between cortical areas and respiratory brainstem centers may be important (71). Functional magnetic resonance imaging (fMRI)-studies on epilepsy patients show reductions in resting-state functional connectivity and tissue loss in cortical, subcortical, and brainstem structures associated with impaired autonomic control and increased SUDEP risk (71–73). However, monitoring of patients who later died from SUDEP did not reveal a direct associated location or lateralization of the epileptogenic zone with their higher risk of death (16). Intracranial EEG recordings and stimulation studies implicate the amygdala, hippocampus, insular cortex, and seizure spread to the contralateral temporal lobe to correlate with ictal cardiorespiratory dysfunctions (32, 36, 53, 65, 67, 74). Thus, identifying the detailed and complex connectivity and the altered brain activity in regions controlling cardiorespiratory activity is crucial for SUDEP risk estimation.

## Control of autonomic functions in the brainstem and SUDEP

Here, we review evidence of brainstem alterations (e.g., genetic or physiological/structural resulting from chronic epilepsy) associated with SUDEP risk. We discuss crucial brainstem areas generating and modulating autonomic rhythms, such as breathing, and discuss their potential role in SUDEP. The respiratory network flexibly adapts to environmental and metabolic changes while maintaining stability to guarantee effective gas exchange (75). This network integrates brainstem rhythm-generating nuclei with other central and peripheral neural regions (76). The brainstem respiratory network includes the parafacial respiratory group (pFRG), Bötzinger complex (BötC), pre-Bötzinger complex (pre-BötC), rostral ventral respiratory group (rVRG), and caudal VRG (cVRG). Pontine nuclei modulate respiratory activity via projections to medullary respiratory nuclei (34, 76, 77). The post-inspiratory complex (PiCo) provides excitatory input to generate post-inspiration patterns (78). Seizure-related effects on respiratory and cardiac brainstem centers can impair these functions and contribute to SUDEP (20, 21, 79, 80) (Figure 1). Cardiorespiratory dysfunction in SUDEP could result from the effects of higher cortical and limbic areas on brainstem function, direct brainstem alterations, or both, including descending and ascending circuitries (27, 38, 81) (Figure 2). Chronic alterations of respiratory control, such as reduced ventilatory responses to increased CO2 levels, occur in epilepsy patients (82).

Epileptic seizures can directly alter heart rhythms and heart rate variability (HRV), which reflects balanced sympathetic and parasympathetic activity (83–86). High sympathetic tone and elevated levels of several neuropeptides can follow seizures (87, 88). Other seizure-induced acute changes include asystole, brady- and tachy-arrhythmias are most common with seizure foci in paralimbic and limbic cortices (69) and may contribute to SUDEP (23, 89, 90). Reduced HRV can result from voltagegated sodium channel gene variants (91), and low-frequency HRV power is associated with SUDEP risk (92). Temporal lobe seizures may disturb arousal and vigilance networks (93).

A critical challenge is distinguishing indirect vs. direct effects on brainstem autonomic centers. For example, PreBötC dysfunction can result from mutations in ion channels (94–96) and mitochondrial genes (97), as well as transcription factors (98). In animal SUDEP models with *Kcna1* and *Scn1a* mutations, the threshold to trigger brainstem SD is reduced (21). However, respiratory networks are state-dependent; neuromodulators influencing respiratory activity include norepinephrine, serotonin, acetylcholine, substance P,




group: VRG. Ventral respiratory group.

ATP, somatostatin, dopamine, endorphins, and adenosine (99). Several have been shown to be elevated during and following seizures and potentially could contribute to SUDEP (88, 100–102).

The brainstem is crucial for controlling cardiorespiratory autonomic function impairments likely contribute to sudden infant death syndrome (SIDS), the sudden and unexpected death of a seemingly healthy baby under age 1 year (103–105). There are striking similarities between SIDS, sudden unexplained death in childhood (SUDC), and SUDEP (106–109) with the exclusion of other causes, nocturnal occurrence in the prone position, and an unwitnessed death (106). Arousal can be triggered by increased CO<sub>2</sub> (hypercapnia) and reduced oxygen levels (hypoxia), further preventing a build-up of end-tidal CO<sub>2</sub> and restoration of normal oxygen levels (103). This arousal response is linked to breathing and is normally initiated with a sigh (augmented breath) (110–112). Sighs are generated in the

PreBötC by the same rhythm-generating network crucial for eupnea and gasping (95, 113). In addition, several other areas such as the dorsal raphe nucleus, the nucleus tractus solitarius, the parabrachial nucleus, and the retrotrapezoid nucleus are involved in arousal (106). Seizures in the amygdala [bed nucleus of the stria terminalis (BNST)] can activate projections to the brainstem, disturbing structures like the parabrachial nucleus involved in arousal and respiratory function (40). The BNST is highly interconnected to cortical regions, the hippocampus, the hypothalamus, the midbrain, and other brainstem nuclei and may serve as an integrator of autonomic and neuroendocrine responses (40, 114-117). As discussed above, massive release of neuromodulators (e.g., norepinephrine, serotonin, and acetylcholine) can disturb arousal. Since hypoxia and hypercapnia trigger arousal and gasping, they are a focus of SIDS research. However, another vulnerability phase is reoxygenation after a hypoxia/hypercapnia. This phase includes



post-hypoxic ventilatory depression (118, 119), which can occur after generalized tonic-clonic seizures and could be potentially prolonged in SUDEP. To dissect these mechanisms, modern experimental technology, including optogenetics and chemogenetics in animal models, as discussed below, is critical.

Future directions of SUDEP research seek to identify common molecular and cellular changes overlapping in several SUDEP animal models and potentially identify common changes in SIDS and SUDC models. While expression changes in RNA levels in brainstem areas of animals showing SD in cortical areas were detected (120), more investigations in epileptic animal models (genetic and induced) are needed to unravel molecular changes that participate in SUDEP.

### ASM and brainstem function

Another potential SUDEP mechanism is direct ASM effects on brainstem function. ASM can reduce SUDEP risk by a

reduction of seizure frequency and severity, thereby preventing seizure-induced impairment of brainstem autonomic centers. Under normal oxygen concentrations, mammals are eupneic, their robust respiratory network combines diverse synaptic and intrinsic signals in the respiratory network (99). During severe hypoxia, the respiratory network generates gasping (121, 122) through reduced mechanisms of rhythm generation (99, 113). During gasping, changes include reduced inhibition (123) and a switch to sodium-dependent intrinsic neuronal bursting securing rhythm generation (124-126). These altered rhythm-generating properties of the respiratory network alter the sensitivity to sodium channel-blocking ASMs and may interrupt the gasping response during seizure-induced postictal hypoxia (127). These direct brainstem effects may contribute to increased mortality associated with lamotrigine use observed in some studies (128). Moreover, during seizures, patients can experience repeated hypoxic episodes combined with increased norepinephrine and other neurotransmitter/modulator levels. This combination can destabilize PreBötC function (129)


and may parallel secondary changes induced by the hypoxic conditions during and after cortical seizures.

More investigations of the brainstem function and gene expression of the brainstem areas controlling respiratory and cardiac functions are needed in epileptic mice to get a better understanding of the mechanisms underlying SUDEP. New insights into chronic brainstem changes could stem from novel techniques of brainstem transcriptome using single-cell RNA-Seq or spatial transcriptomics (130).

## Model systems for studying epilepsy and SUDEP

Model systems help to investigate the pathological interactions between brain regions that can result in a collapse of cardiorespiratory function and SUDEP. *In vitro* and *in vivo* models can study neuronal disease network mechanisms (131–133). *In vitro* models standardize experimental conditions, but oversimplify neuronal network function or whole organism interaction, which may be critical in SUDEP. *In vivo* models comprise diverse methods and model organisms (134–138). Brain areas involved in epileptic activity and cardiorespiratory regulation are similar in mice and humans (78, 139) (Figures 2A, B). Thus, mice can appropriately model human epilepsy. Modern techniques can target specific brain areas and predefined neuronal cell populations to decipher their role in epilepsy and SUDEP (140).

Epilepsy can result from diverse pathological processes, including trauma, stroke, tumors, infections, autoimmune disorders, and >150 genetic variants (141, 142). Epilepsy is often accompanied by comorbid disorders, including autism spectrum, cognitive, psychiatric, and hyperkinetic (143-148). The developmental and epileptic encephalopathies (DEEs) include a diverse spectrum of early-life epilepsies, often resulting from genetic disorders, and associated with developmental delays partly attributable to seizures and interictal epileptiform activity (149). Across these disorders, E/I imbalances occur in the amygdala, cortex, hippocampus, and other epileptogenic regions (150, 151). Complex and heterogeneous genetic mouse models recapitulate various human pathologies, offering insights into epilepsy and SUDEP and allowing controlled experiments on mechanisms by controlling for different confounds. Epilepsy mouse models are divided into induced and genetic models. In kindling models, stimulation (electrical, chemical, or acoustic) induces seizures, whereas in genetic models, gene mutations result in spontaneous seizures (136, 152). Mouse models can mimic focal and generalized epilepsies as well as post-traumatic epilepsy (153), temporal lobe epilepsy (TLE) (152), genetic variants (80, 154), and scores of rare genetic disorders (e.g., tuberous sclerosis complex, CDKL5, Rett Syndrome, Dravet Syndrome, FOXG1 syndrome, STXBP1 syndrome and many more) (Figure 3).



Some genetically modified mouse lines model SUDEP with deadly seizure-induced cardiorespiratory abnormalities (39, 155). Many genetic models involve ion channels, including sodium voltage-gated channels (Na<sub>v</sub>) (154, 156–158), potassium voltage-gated channels (K<sub>v</sub>) (28, 159, 160), or calcium voltage-gated channels (Ca<sub>v</sub>) (30, 161) (Table 1). Some display spontaneous epileptic seizures (e.g., *Scn1a*, *Scn1b*, *Kcna1*, *Kcnq1*, *Cacna1a*, *Shank3*) (31, 143, 159, 162, 163) while others are susceptible to heat or audiogenic-induced seizures (e.g. Scn1a, Scn8a, DBA/1) (80, 164) (Figure 3).

Commonly SUDEP mouse models carry mutations in the Nav (1.1, 1.6) and Kv (1.1, 7.1, 11.1) genes (159, 162, 165). Scn1a mutations alter the  $Na_v\alpha 1$  subunit (Na<sub>v</sub>1.1) and Nav1.1 haploinsufficiency can cause Dravet Syndrome (DS). DS is a treatment-resistant early-onset epilepsy with 70-80% of cases due to Scn1a variants and high rates of SUDEP (9, 83, 166-169). Nav1.1 is expressed in inhibitory neurons. A loss of function decreases their excitability, increasing network excitability, altering action potential (AP) dynamics (170-173) and impairs thalamic glutamatergic and GABAergic function, disrupting thalamocortical networks and facilitating seizure generation (174, 175). Nav1.1 deficient mice recapitulate many aspects of human DS pathology including severe epilepsy, multiple neuropsychiatric comorbidities, and increased SUDEP risk (21, 22, 83, 173, 176-180). Other gene mutations (e.g., Scn1b and Scn8a) display similar symptoms (163, 164, 181, 182). Mice with mutations in genes encoding for K<sub>v</sub> show cardiorespiratory failure including cardiac abnormalities and apnea observed in SUDEP (21, 183).  $K_v 1.1-\alpha 1$  subunits, encoded by the Kcna1 gene, are crucial for neuronal excitability and are broadly expressed in the cortex, hippocampus, cerebellum, and brainstem (184, 185). Kcna1 knockout mice display earlyonset generalized tonic-clonic seizures, seizure-related death,

| Gene    | Channel   | Expression   | Disorder   | Studies                          |
|---------|---|--|--|----------------------------------|
| SCN1A   | $\mathrm{Na^{+}}$ channel ( $\alpha$ subunit of $\mathrm{Na_v1.1})$ | Central nervous system and cardiac myocytes                              | Genetic epilepsy with febrile<br>seizures plus (GEFS+), Dravet<br>Syndrome | (22, 169, 170, 173, 174,<br>191) |
| SCN1B   | $\mathrm{Na}^+$ channel ( $\beta$ subunit of $\mathrm{Na}_v 1.1)$   | Central and peripheral nervous<br>system, skeletal, and cardiac muscles. | Genetic epilepsy with febrile<br>seizures plus (GEFS+)                     | (163, 181)                       |
| SCN8A   | $\rm Na^+$ channel ( $\alpha$ subunit of $\rm Na_v 1.6)$            | Central nervous system   | Epilepsy   | (148, 154, 164, 182)             |
| KCNA1   | $K^+$ channel ( $\alpha$ subunit of $K_v 1.1)$                      | Central and peripheral nervous system                                    | Epilepsy, Episodic ataxia  | (159, 160, 183, 187)             |
| KCNH2   | K <sup>+</sup> channel (K <sub>v</sub> 11.1)                        | Brain and heart  | Long QT syndrome   | (165, 189)                       |
| KCNQ1   | K <sup>+</sup> channel (K <sub>v</sub> 7.1)                         | Heart, intestinal cells  | Long QT syndrome   | (162)                            |
| CACNA1A | $Ca^{2+}$ channel ( $\alpha$ subunit of $Ca_v2.1)$                  | Brain  | Epilepsy, Familial hemiplegic<br>migraine, Episodic ataxia                 | (30, 31, 35, 161)                |

TABLE 1 Overview of common channelopathies in mouse models of epilepsy and SUDEP.

and cardiorespiratory dysfunction (159, 186–188). These mice exhibit apneas, increased respiratory variability, and precede cardiac failure as risk factors for SUDEP (183, 187). Further  $K_v$ -channelopathies (e.g., *Kcnh2* and *Kcnq1*) are susceptible to recurrent seizures and long QT syndrome (LQTS); i.e., arrhythmias and SUDEP (162, 189, 190).

Mutations in genes encoding for Na<sub>v</sub>1.1, K<sub>v</sub>1.1, and Ca<sub>v</sub>2.1 are moreover linked to brainstem seizures, medullary SD, and cortical seizures propagating to the brainstem causing cardiorespiratory arrest (21, 30, 31, 35). Thereby, local brainstem SD can elicit EEG suppression, apnea, bradycardia, and asystole, mimicking the involvement of SD in epileptic activity propagation and its relevance as SUDEP models.

Thus, a number of model systems and especially mouse models, are nowadays available for epilepsy and SUDEP research. In the direct context of SUDEP, models with Na<sub>v</sub> (1.1, 1.6) and K<sub>v</sub> (1.1, 7.1, 11.1) mutations seem particularly promising. Of these, *Scn1a* models have been extensively studied and largely model the human SUDEP pathology and phenotypes well (152, 167, 191). Future studies need to extend to clinically and genetically characterized epilepsies to explore if common or distinct pathways of autonomic dysfunction mediate SUDEP.

## Techniques to study network interaction involved in SUDEP


To understand SUDEP mechanisms, we need models and techniques to represent and measure cortical seizure generation and propagation as well as cardiorespiratory function. *In vivo* techniques allow direct epileptic activity measurements and manipulations (192, 193) of complex circuitries and brain connections. *Ex vivo* recordings from targeted brain regions allow cellular processes to be investigated at high resolution. *Ex vivo* measurements like histological reconstructions, stainings,

and spatial transcriptomics (180, 194) can reveal anatomical brain changes associated with epilepsy, which may be the cause or effect of epilepsy or an epiphenomenon of the underlying pathology.

Next, we will discuss recent advancements in methods to investigate *in vivo* and *ex vivo* models, including optogenetics, electrophysiology, imaging, and other measurements (Figure 4).

Optogenetics is a technique to study specific cells and their relations to brain functions and disorders (195). Optogenetics utilizes the expression of light-sensitive proteins (opsins) in brain areas or specific cells. Depending on the opsin used, targeted neurons can be activated or inhibited (or even both) using light stimulation to precisely control neuronal activity. Optogenetics can trigger or prevention of epileptic activity (196) with millisecond temporal precision, enabling the assessment of how specific firing patterns affect brain cells and networks (197). Optogenetics can be applied invasively and non-invasively (198) and can be combined with electrophysiological recordings and imaging techniques. Chemogenetics can selectively modulate cellular pathways using restricted artificial chemogenetic receptors [e.g. DREADDs (Designer Receptors Exclusively Activated by Designer Drugs)] delivered to specific neuronal populations. Instead of light stimulation, chemogenetics systemically injected or microinfused can activate ligands that excite or inhibit targeted neurons (199). Optogenetics can be combined with chemogenetics to manipulate neuronal activity with a high temporal and spatial resolution (200). In epilepsy animal models, these combined methods can identify and manipulate specific neuron populations, brain regions, and neuronal circuitries involved in epileptic activity (201).

Seizures and interictal epileptic discharges (IEDs) can be restricted to certain brain regions and networks. Electroencephalographic (EEG) recordings can localize brain regions giving rise to seizures and examine epilepsy-related




neuronal activity changes across brain regions (202). Scalp EEG records changes in electrical potentials caused by ion flow across neural membranes, mainly at the brain's surface. It can detect the origin and propagation of epileptic activity throughout different brain regions at a macro scale (203, 204) (Figure 4A). Invasive methods include intracranial EEG (iEEG) using depth or subdural EEG recordings (ECoG) to study seizure onset and spread as well as SD and seizure propagation in SUDEP models at a higher spatiotemporal resolution (22, 30). Stereotaxically inserted multi-channel electrodes can record local field potentials (LFPs) and single-cell activity (204, 205). Modulation of neuronal activity via electrical stimulation with these electrodes is possible but is much less precise than optogenetic manipulation. For example, SDs can be induced by electrical, and optogenetic techniques (206) whereas electrophysiological and optical recording methods can assess their propagation and effects on other structures (207, 208).

Combined optogenetics and electrophysiology *in vivo*, using optical microelectrodes are called *optrodes* (209, 210)

enabling a direct readout of manipulated cell activity. Here, a single microelectrode probe with integrated optical fiber can simultaneously record and transmit light to genetically modified, opsin-expressing cells. Optrodes can study neuronal circuit dynamics in awake-behaving animals (211, 212) (Figure 4B).

Imaging allows the visualization/mapping of cortical activity with high spatial and temporal resolution (213, 214). Voltagesensitive dyes (VSDs) or genetically encoded calcium indicators (GECIs) react to direct or indirect ( $Ca^{2+}$ ) changes in neuronal activity. VSD imaging incorporates dyes into the cell membrane that signal membrane-potential differences as changes in fluorescence. VDS imaging can monitor synaptic transmission and propagation of cortical activity but has a low signal-tonoise ratio and lacks cellular specificity (215, 216). GECIs allow cell-specific targeting but have a slower temporal resolution. GECIs have been used to record population activity in widefield calcium imaging experiments. Combined with two-photon imaging, GECIS can reveal activity dynamics of hundreds of



individual neurons (217). Since the activity-dependent changes in calcium-sensitive proteins can be visualized *in vivo* over months, large-scale longitudinal functional studies can assess activity before, during, and after seizures and in a single animal (Figure 4C). Imaging techniques can visualize seizures *in vivo* at high temporal and cellular resolution (172, 218).

Fiber photometry can combine imaging and optogenetics using an implanted fiber-optic cannula to deliver excitation pulses and monitor activity-dependent fluorescence changes (219). This technique is ideal for deep brain recordings and can study calcium signals in distinct epileptic brain regions in freely moving mice (220) (Figure 4D). Fiber photometry can be used simultaneously with electrophysiological recordings to combine cell-type-specific imaging with high temporal-resolution spike recordings in freely behaving mice (221).

These methods have provided new insights into the role of brain regions and cell populations in epilepsy. Optogenetics combined with optical manipulation, and electrophysiological recordings revealed the key role of inhibitory GABAergic interneuron signaling in seizure generation and ictal propagation in epileptic mice (212, 222). Other studies addressing brainstem excitatory neurons showed a direct correlation to reduced subcortical activity during seizures (223). Together, these techniques provide new research opportunities on epilepsy networks and seizure dynamics over the whole brain.

Investigating SUDEP and cardiorespiratory dysfunctions requires additional recording techniques for *in vivo* monitoring of autonomic functions including breathing and heart rate. Several methods are available in the mouse (155, 182, 183, 224). Cardiac activity is typically recorded *via* electrocardiography (ECG) (225, 226). Methods can monitor breathing (227) including invasive (telemetry systems and intranasal cannulas)

and non-invasive methods (movement sensors, restraining systems, plethysmographs) (Figure 5). The whole-chamber plethysmography approach offers a non-invasive method in freely, non-restrained animals (95, 97, 228). This technique allows recordings of breathing under hypoxia/hypoxemia conditions (low blood oxygen levels and insufficient oxygen supply) linked to SUDEP (30, 52, 229).

Although *in vivo* methods provide insights into the network mechanisms, *ex vivo* studies offer more focused investigations of cellular changes. Histological reconstructions and stainings of brain regions can follow *in vivo* experiments to verify transgene expressions and precisely localize implanted electrodes or optical fibers (30, 180, 230). Brain slice preparations containing cortical, hippocampal, or brainstem microcircuits allow single-cell recordings or small network analysis to gain insights into pathophysiology (78, 95, 231, 232). Spatial transcriptomics can map the organization and connectivity of distinct genetically defined cell types (194, 233). In epilepsy research, this can provide a deeper exploration of disease mechanisms and pathogenic changes in the spatial organization and molecular signaling networks (234).

Thus, combining different techniques can provide a greater definition of the dysfunctions associated with epileptic activity and its interplay with autonomic functions on different levels to identify possible biomarkers for epilepsy, seizure onset, and SUDEP (202, 235).

Possible therapeutic approaches could be based on electrical or optical stimulation of specific brain areas to "rebalance" their E/I activity and maintain cardiorespiratory function during and after seizures (198, 236). Electrical stimulation in patients to map epileptic zones can inhibit or enhance respiration (237). Optogenetic neuronal activation has been shown to suppress seizure-induced respiratory arrest and exert an anticonvulsant effect in a SUDEP mouse model (238). Further, *ex vivo* methods might provide opportunities for new molecular targets and drug screening (233, 234, 239). However, these invasive approaches will require far more refinement for their potential benefits to exceed their definite risks.

#### Conclusion and future perspectives

SUDEP is the leading epilepsy-related cause of death, affecting all age groups and epilepsy severities. SUDEP mechanisms are poorly understood but are critical for preventive and therapeutic strategies. Although ASMs can control seizures in most patients, they do not alter long-term prognosis or cure epilepsy (240). Further, their side effects can be severe (241, 242). 30% of the patients with ASM-resistant epilepsy suffer ongoing seizures and experience an increased SUDEP risk. Medications/treatments that prevent seizures in those that are currently uncontrolled with minimal side effects are desperately needed. Understanding SUDEP mechanisms in more detail is a desperate need.

Epilepsy mouse models with ion channel mutations mimic human epilepsies (176) and are critical in translational neuroscience research (243). They offer possibilities to investigate the link between genetic alterations and their underlying neurobiological mechanisms in much greater detail compared to humans. Translation of basic animal research to human epilepsy is exemplified by *SCN1A*-mice whose response to ASM has enabled the development of FDA-approved medications and gene therapy trials (191). Translational research with new molecular targets for anti-epileptogenic and anti-seizure research can empower novel drug discoveries and identify potential biomarkers for early diagnoses and more effective treatments (235, 243, 244).

Cardiorespiratory inhibition following epileptic seizures may be the common final mechanism of SUDEP. Cardiorespiratory dysfunctions from cortical or subcortical epileptic activity propagating to brainstem regions could cause SUDEP (21, 30, 31). SD might be directly involved in SUDEPrelated seizure spread to the brainstem (29). Mouse models combining technological advances allow precise investigations of the brain networks implicated in SUDEP (235). These brain areas may provide new targets for interventions to prevent SUDEP.

In mice, invasive methods such as optical or electrical stimulations can manipulate neuronal networks (198, 245) whereas neurostimulation-based techniques can also be applied to epilepsy patients. Acute and chronic deep brain stimulation (DBS), as well as vagus nerve stimulation (VNS), are epilepsy

therapies (236, 246–248). Combining neurostimulation and ASM may be more effective in controlling seizures than either alone (249).

There remains a critical need to better understand the mechanisms of epilepsy and SUDEP. Mouse models combined with precise methods are an important tools to assess these mechanisms and translate this knowledge into preventive and therapeutic strategies.

### Author contributions

JB, OD, MR, and HK reviewed the literature and wrote this review article. All authors contributed to the article and approved the submitted version.

#### Funding

This study was supported by the Deutsche [DFG, Forschungsgemeinschaft German Research Foundation, 250583768/RO4046/2-1 and /2-2 (MR), 445965029/RO4046/5-1 (MR), 466488864/RO4046/6-1 and 7-1 (MR), 368482240/GRK2416 (MR)], 263938822/KO-4877/2-1 and the Interdisciplinary Center for Clinical Research within the faculty of Medicine at the RWTH Aachen University Grant IZKF TN1-7 532007 (MR) and FACES (Finding a Cure for Epilepsy and Seizures) (HK).

#### Acknowledgments

Figures were partly created with Biorender.com.

### **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

#### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

### References

1. Beghi, E., Giussani, G., Nichols, E., Abd-Allah, F., Abdela, J., Abdelalim, A., et al.L. (2019). Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 18, 357–375. doi: 10.1016/S1474-4422(18)30454-X

2. Beghi E. The epidemiology of epilepsy. *Neuroepidemiology*. (2020) 54:185–91. doi: 10.1159/000503831

3. Fisher RS, Van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). *Epilepsia*. (2005) 46:470–2. doi: 10.1111/j.0013-9580.2005.66104.x

4. Cuello Oderiz C, von Ellenrieder N, Dubeau F, Eisenberg A, Gotman J, Hall J, et al. Association of cortical stimulation-induced seizure with surgical outcome in patients with focal drug-resistant epilepsy. *JAMA Neurol.* (2019) 76:1070–78. doi: 10.1001/jamaneurol.2019.1464

5. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology. *Epilepsia*. (2017) 58:522–30. doi: 10.1111/epi.13670

6. Berto P. Quality of life in patients with epilepsy and impact of treatments. *Pharmacoeconomics.* (2002) 20:1039–59. doi: 10.2165/00019053-200220150-00002

7. Kwan, P., and Brodie, M. (2000). Early identification of refractory epilepsy. N Engl J Med., 342, 314–319. doi: 10.1056/NEJM200002033420503

8. Sveinsson O, Andersson T, Carlsson S, Tomson T. The incidence of SUDEP: A natiowide population-based cohort study. *Neurology*. (2017) 89:170–7. doi: 10.1212/WNL.00000000004094

9. Devinsky O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson G. Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. *Lancet Neurol.* (2016) 15:1075–88. doi: 10.1016/S1474-4422(16)30158-2

10. Surges R, Thijs RD, Tan HL, Sander JW. Sudden unexpected death in epilepsy: risk factors and potential pathomechanisms. *Nat Rev Neurol.* (2009) 5:492–504. doi: 10.1038/nrneurol.2009.118

11. Tomson T, Walczak T, Sillanpaa M, Sander J. Sudden unexpected death in epilepsy: a review of incidenceand risk factors. *Epilepsia.* (2005) 46:54–61. doi: 10.1111/j.1528-1167.2005.00411.x

12. Thurman DJ, Hesdorffer DC, French JA. Sudden unexpected death in epilepsy: assessing the public health burden. *Epilepsia*. (2014) 55:1479–85. doi: 10.1111/epi.12666

13. Sveinsson O, Andersson T, Mattsson P, Carlsson S, Tomson T. Pharmacologic treatment and SUDEP risk: A nationwide, population-based, case-control study. *Neurology.* (2020) 95:e2509–18. doi: 10.1212/WNL.000000000010874

14. van der Lende M, Hesdorffer DC, Sander JW, Thijs RD. Nocturnal supervision and SUDEP risk at different epilepsy care settings. *Neurology*. (2018) 91:e1508–18. doi: 10.1212/WNL.00000000006356

15. Devinsky O, Friedman D, Cheng JY, Moffatt E, Kim A, Tseng ZH, et al. Underestimation of sudden deaths among patients with seizures and epilepsy. *Neurolgy.* (2017) 89:886–92. doi: 10.1212/WNL.00000000004292

16. Nei M, Ho RT, Abou-Khalil BW, Drislane FW, Liporace J, Romeo A, et al. EEG and ECG in sudden unexplained death in epilepsy. *Epilepsia.* (2004) 45:338–45. doi: 10.1111/j.0013-9580.2004.05503.x

17. Verducci C, Hussain F, Donner E, Moseley BD, Buchhalter J, Hesdorffer D, et al. SUDEP in the North American SUDEP registry: the full spectrum of epilepsies. *Neurology*. (2019) 93:e227–36. doi: 10.1212/WNL.000000000007778

18. Blum A. Respiratory physiology of seizures. J Clin Neurophysiol. (2009) 26:309–15. doi: 10.1097/WNP.0b013e3181b7f14d

19. Lamberts RJ, Thijs RD, Laffan A, Langan Y, Sander JW. Sudden unexpected death in epilepsy: people with nocturnal seizures may be at highest risk. *Epilepsia*. (2012) 53:253–7. doi: 10.1111/j.1528-1167.2011.03360.x

20. Ryvlin P, Nashef L, Lhatoo SD, Bateman LM, Bird J, Bleasel A, et al. Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. *Lancet Neurology.* (2013) 12:966–77. doi: 10.1016/S1474-4422(13)70214-X

21. Aiba I, Noebels JL. Spreading depolarization in the brainstem mediates sudden cardiorespiratory arrest in mouse SUDEP models. *Sci Transl Med.* (2015) 7:246. doi: 10.1126/scitranslmed.aaa4050

22. Kalume F, Westenbroek RE, Cheah CS, Yu FH, Oakley JC, Scheuer T, et al. Sudden unexpected death in a mouse model of Dravet syndrome. *J Clin Invest.* (2013) 123:1798–808. doi: 10.1172/JCI66220

23. Leung H, Kwan P, Elger CE. Finding the missing link between ictal bradyarrhythmia, ictal asystole, and sudden unexpected death in epilepsy. *Epilepsy Behav.* (2006) 9:19–30. doi: 10.1016/j.yebeh.2006.05.009

24. Derera ID, Delisle BP, Smith BN. Functional neuroplasticity in the nucleus tractus solitarius and increased risk of sudden death in mice with acquired temporal lobe epilepsy. *eNeuro*. (2017) 4:5. doi: 10.1523/ENEURO.0319-17.2017

25. Lertwittayanon W, Devinsky O, Carlen PL. Cardiorespiratory depression from brainstem seizure activity in freely moving rats. *Neurobiol Dis.* (2020) 134:104628. doi: 10.1016/j.nbd.2019.104628

26. Pilar M, DeFelipe J. Altered synaptic circuitry in the human temporal neocortex removed from epileptic patients. *Exp Brain Res.* (1997) 114:1–10. doi: 10.1007/PL00005608

27. Yackle K, Schwarz LA, Kam K, Sorokin JM, Huguenard JR, Feldman JL, et al. Breathing control center neurons that promote arousal in mice. *Science*. (2017) 355:1411–5. doi: 10.1126/science.aai7984

28. Aiba I, Noebels JL. Kcnq2/Kv7.2 controls the threshold and bi-hemispheric symmetry of cortical spreading depolarization. *Brain.* (2021) 144:2863–78. doi: 10.1093/brain/awab141

29. Cozzolino O, Marchese M, Trovato F, Pracucci E, Ratto GM, Buzzi MG, et al. Understanding spreading depression from headache to sudden unexpected death. *Front Neurol.* (2018) 9:19. doi: 10.3389/fneur.2018.00019

30. Jansen NA, Schenke M, Voskuyl RA, Thijs RD, van den Maagdenberg A, Tolner EA, et al. Apnea associated with brainstem seizures in Cacna1a (S218L) mice is caused by medullary spreading depolarization. *J Neurosci.* (2019) 39:9633– 44. doi: 10.1523/JNEUROSCI.1713-19.2019

31. Loonen ICM, Jansen NA, Cain SM, Schenke M, Voskuyl RA, Yung AC, et al. Brainstem spreading depolarization and cortical dynamics during fatal seizures in Cacna1a S218L mice. *Brain.* (2019) 142:412–25. doi: 10.1093/brain/awy325

32. Dlouhy BJ, Gehlbach BK, Kreple CJ, Kawasaki H, Oya H, Buzza C, et al. Breathing inhibited when seizures spread to the amygdala and upon amygdala stimulation. *J Neurosci.* (2015) 35:10281–9. doi: 10.1523/JNEUROSCI.0888-15.2015

33. Herrero JL, Khuvis S, Yeagle E, Cerf M, Mehta AD. Breathing above the brain stem: volitional control and attentional modulation in humans. *J Neurophysiol.* (2018) 119:145–59. doi: 10.1152/jn.00551.2017

34. Yang CF, Feldman JL. Efferent projections of excitatory and inhibitory preBotzinger Complex neurons. *J Comp Neurol.* (2018) 526:1389–402. doi: 10.1002/cne.24415

35. Cain SM, Bernier LP, ZhangY, Yung AC, Kass J, Bohnet B, et al. Hyperexcitable superior colliculus and fatal brainstem spreading depolarization in a model of sudden unexpected death in epilepsy. *Brain Commun.* (2022) 4:fcac006. doi: 10.1093/braincomms/fcac006

36. Nobis WP, Gonzalez Otarula KA, Templer JW, Gerard EE, VanHaerents S, Lane G, et al. The effect of seizure spread to the amygdala on respiration and onset of ictal central apnea. *J Neurosurg.* (2019) 132:1313–23. doi: 10.3171/2019.1.JNS183157

37. Jarre G, Altwegg-Boussac T, Williams MS, Studer F, Chipaux M, David O, et al. Building up absence seizures in the somatosensory cortex: from network to cellular epileptogenic processes. *Cereb Cortex.* (2017) 27:4607–23. doi: 10.1093/cercor/bhx174

38. Karalis N, Sirota A. Breathing coordinates cortico-hippocampal dynamics in mice during offline states. *Nat Commun.* (2022) 13:467. doi: 10.1038/s41467-022-28090-5

39. Marincovich A, Bravo E, Dlouhy B, Richerson GB. Amygdala lesions reduce seizure-induced respiratory arrest in DBA/1 mice. *Epilepsy Behav.* (2021) 121:106440. doi: 10.1016/j.yebeh.2019.07.041

40. Yan WW, Xia M, Chiang J, Levitt A, Hawkins N, Kearney J, et al. Enhanced synaptic transmission in the extended amygdala and altered excitability in an extended amygdala to brainstem circuit in a dravet syndrome mouse model. *eNeuro*. (2021) 8:3. doi: 10.1523/ENEURO.0306-20. 2021

41. Kostopoulus G. Involvement of the thalamocortical system in epileptic loss of consciousness. *Epilepsia*. (2001) 42:13–9. doi: 10.1046/j.1528-1157.2001.042suppl. 3013.x

42. Bonansco C, Fuenzalida M. Plasticity of hippocampal excitatoryinhibitory balance: missing the synaptic control in the epileptic brain. *Neural Plast.* (2016) 2016:8607038. doi: 10.1155/2016/86 07038 43. Liou JY, Smith EH, Bateman LM, Bruce SL, McKhann GM, Goodman RR, et al. A model for focal seizure onset, propagation, evolution, and progression. *Elife.* (2020) 9: 50927. doi: 10.7554/eLife.50927

44. Eissa TL, Dijkstra K, Brune C, Emerson RG, van Putten M, Goodman RR, et al. Cross-scale effects of neural interactions during human neocortical seizure activity. *Proc Natl Acad Sci U S A.* (2017) 114:10761–6. doi: 10.1073/pnas.1702490114

45. Schevon CA, Weiss SA, McKhann GJr, Goodman RR, Yuste R, Emerson RG, et al. Evidence of an inhibitory restraint of seizure activity in humans. *Nat Commun.* (2012) 3:1060. doi: 10.1038/ncomms2056

46. Chever O, Zerimech S, Scalmani P, Lemaire L, Pizzamiglio L, Loucif A, et al. Initiation of migraine-related cortical spreading depolarization by hyperactivity of GABAergic neurons and NaV1, 1 Channels. *J Clin Invest.* (2021) 131:21. doi:10.1172/JCl142203

47. Bigal ME, Lipton RB, Cohen J, Silberstein SD. Epilepsy and migraine. *Epilepsy Behav.* (2003) 4:S13–24. doi: 10.1016/j.yebeh.2003.07.003

48. Charles AC, Baca SM. Cortical spreading depression and migraine. *Nat Rev Neurol.* (2013) 9:637–44. doi: 10.1038/nrneurol.2013.192

49. Rho YI, Kim SH, Kang HC, Lee YJ, Kim YO, Kim SK, et al. EEG Characteristics and diagnostic implications in childhood headache: a multi-center study. *Front Neurol.* (2020) 11:569486. doi: 10.3389/fneur.2020.569486

50. Rogawski MA. Migraine and epilepsy-shared mechanisms within the family of episodic disorders. *Jasper's Basic Mech Epilepsies*. (2012) 51:1–5. doi: 10.1093/med/9780199746545.003.0073

51. Chong CD, Plasencia JD, Frakes DH, Schwedt TJ. Structural alterations of the brainstem in migraine. *Neuroimage Clin.* (2017) 13:223-7. doi: 10.1016/j.nicl.2016.10.023

52. Bateman LM, Li CS, Seyal M. Ictal hypoxemia in localization-related epilepsy: analysis of incidence, severity and risk factors. *Brain.* (2008) 131:3239–45. doi: 10.1093/brain/awn277

53. Seyal M, Bateman LM. Ictal apnea linked to contralateral spread of temporal lobe seizures: Intracranial EEG recordings in refractory temporal lobe epilepsy. *Epilepsia.* (2009) 50:2557–62. doi: 10.1111/j.1528-1167.2009.02245.x

54. Kang JY, Rabiei AH, Myint L, Nei M. Equivocal significance of post-ictal generalized EEG suppression as a marker of SUDEP risk. *Seizure.* (2017) 48:28–32. doi: 10.1016/j.seizure.2017.03.017

55. Seyal M, Bateman LM, Li CS. Impact of periictal interventions on respiratory dysfunction, postictal EEG suppression, and postictal immobility. *Epilepsia*. (2013) 54:377–82. doi: 10.1111/j.1528-1167.2012.03691.x

56. Surges R, Strzelczyk A, Scott CA, Walker MC, Sander JW. Postictal generalized electroencephalographic suppression is associated with generalized seizures. *Epilepsy Behav.* (2011) 21:271–4. doi: 10.1016/j.yebeh.2011.04.008

57. van den Maagdenberg AM, Pietrobon D, Pizzorusso T, Kaja S, Broos LA, Cesetti T, et al. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. *Neuron.* (2004) 41:701–10. doi: 10.1016/S0896-6273(04)00085-6

58. van den Maagdenberg AM, Pizzorusso T, Kaja S, Terpolilli N, Shapovalova M, Hoebeek FE, et al. High cortical spreading depression susceptibility and migraineassociated symptoms in Ca(v)2.1 S218L mice. *Ann Neurol.* (2010) 67:85–98. doi: 10.1002/ana.21815

59. Leo L, Gherardini L, Barone V, Fusco D, Pietrobon M, et al. Increased susceptibility to cortical spreading depression in the mouse model of familial hemiplegic migraine type 2. *PLoS Genet.* (2011) 7:e1002129. doi: 10.1371/journal.pgen.1002129

60. Auffenberg E, Hedrich UB, Barbieri R, Miely D, Groschup B, Wuttke TV, et al. Hyperexcitable interneurons trigger cortical spreading depression in an Scn1a migraine model. *J Clin Invest.* (2021) 131:21. doi: 10.1172/JCI14 2202

61. Jansen NA, Dehghani A, Linssen MML, Breukel C, Tolner EA, van den Maagdenberg A, et al. First FHM3 mouse model shows spontaneous cortical spreading depolarizations. *Ann Clin Transl Neurol.* (2020) 7:132–8. doi: 10.1002/acn3.50971

62. Tamim I, Chung DY, Morais D, Loonen AL, Qin ICM, Misra T, et al. Spreading depression as an innate antiseizure mechanism. *Nat Commun.* (2021) 12:2206. doi: 10.1038/s41467-021-22464-x

63. Noebels JLMD. Brainstem spreading depolarization: rapid descent into the shadow of SUDEP. *Brain.* (2019) 142:231–3. doi: 10.1093/brain/awy356

64. Park K, Kanth K, Bajwa S, Girgis F, Shahlaie K, Seyal M, et al. Seizure-related apneas have an inconsistent linkage to amygdala seizure spread. *Epilepsia.* (2020) 61:1253–60. doi: 10.1111/epi.16518

65. Lacuey N, Hampson JP, Harper RM, Miller JP, Lhatoo S. Limbic and paralimbic structures driving ictal central apnea. *Neurology*. (2019) 92:e655–69. doi: 10.1212/WNL.00000000006920

66. Lacuey N, Zonjy B, Londono L, Lhatoo SD. Amygdala and hippocampus are symptomatogenic zones for central apneic seizures. *Neurology*. (2017) 88:701–5. doi: 10.1212/WNL.00000000003613

67. Rhone AE, Kovach CK, Harmata GI, Sullivan AW, Tranel D, Ciliberto MA, et al. A human amygdala site that inhibits respiration and elicits apnea in pediatric epilepsy. *JCI Insight.* (2020) 5:134852. doi: 10.1172/jci.insight.134852

68. Leung H, Schindler K, Kwan P, Elger C. Asystole induced by electrical stimulation of the left cingulate gyrus. *Epileptic Disord.* (2007) 9:77–81. doi: 10.1684/epd.2007.0054

69. Sanchez-Larsen A, Principe A, Ley M, Navarro-Cuartero J, Rocamora R. Characterization of the insular role in cardiac function through intracranial electrical stimulation of the human insula. *Ann Neurol.* (2021) 89:1172-80. doi: 10.1002/ana.26074

70. Doi A, Ramirez JM. State-dependent interactions between excitatory neuromodulators in the neuronal control of breathing. *J Neurosci.* (2010) 30:8251–62. doi: 10.1523/JNEUROSCI.5361-09.2010

71. Allen LA, Harper RM, Lhatoo S, Lemieux L, Diehl B. Neuroimaging of sudden unexpected death in epilepsy (SUDEP): insights from structural and resting-state functional MRI studies. *Front Neurol.* (2019) 10:185. doi: 10.3389/fneur.2019.00185

72. Mueller SG, Nei M, Bateman LM, Knowlton R, Laxer KD, Friedman D, et al. Brainstem network disruption: a pathway to sudden unexplained death in epilepsy? *Hum Brain Mapp*. (2018) 39:4820–30. doi: 10.1002/hbm.24325

73. Tang Y, Chen Q, Yu X, Xia W, Luo C, Huang X, et al. A resting-state functional connectivity study in patients at high risk for sudden unexpected death in epilepsy. *Epilepsy Behav.* (2014) 41:33–8. doi: 10.1016/j.yebeh.2014.08.140

74. Afif A, Minotti L, Kahane P, Hoffmann D. Anatomofunctional organization of the insular cortex: a study using intracerebral electrical stimulation in epileptic patients. *Epilepsia.* (2010) 51:2305–15. doi: 10.1111/j.1528-1167.2010.02755.x

75. Ramirez JM, Baertsch N. Defining the Rhythmogenic Elements of Mammalian Breathing. *Physiology*. (2018) 33:302–16. doi:10.1152/physiol.00025.2018

76. Garcia AJ, Zanella S, Koch H, Doi A, Ramirez JM. Chapter 3–networks within networks: the neuronal control of breathing. *Prog Brain Res.* (2011) 188:31–50. doi: 10.1016/B978-0-444-53825-3.00008-5

77. Dutschmann M, Dick TE. Pontine mechanisms of respiratory control. *Compr Physiol.* (2012) 2:2443–69. doi: 10.1002/cphy.c100015

78. Anderson TM, Garcia AJ, Baertsch NA, Pollak J, Bloom JC, Wei AD, et al. A novel excitatory network for the control of breathing. *Nature*. (2016) 536:76–80. doi: 10.1038/nature18944

79. Manolis TA, Manolis AA, Melita H, Manolis AS. Sudden unexpected death in epilepsy: The neuro-cardio-respiratory connection. *Seizure*. (2019) 64:65–73. doi: 10.1016/j.seizure.2018.12.007

80. Schilling WP, McGrath MK, Yang T, Glazebrook PA, Faingold CL, Kunze DL, et al. Simultaneous cardiac and respiratory inhibition during seizure precedes death in the DBA/1 audiogenic mouse model of SUDEP. *PLoS One.* (2019) 14:e0223468. doi: 10.1371/journal.pone.0223468

81. Yang CF, Kim EJ, Callaway EM, Feldman JL. Monosynaptic Projections to Excitatory and Inhibitory preBotzinger Complex Neurons. *Front Neuroanat.* (2020) 14:58. doi: 10.3389/fnana.2020.00058

82. Sainju RK, Dragon DN, Winnike HB, Nashelsky MB, Granner MA, Gehlbach BK, et al. Ventilatory response to  $CO_2$  in patients with epilepsy. *Epilepsia.* (2019) 60:508–17. doi: 10.1111/epi.14660

83. Kalume F. Sudden unexpected death in Dravet syndrome: respiratory and other physiological dysfunctions. *Respir Physiol Neurobiol.* (2013) 189:324–8. doi: 10.1016/j.resp.2013.06.026

84. Massey CA, Sowers LP, Dlouhy BJ, Richerson GB. Mechanisms of sudden unexpected death in epilepsy: the pathway to prevention. *Nat Rev Neurol.* (2014) 10:271–82. doi: 10.1038/nrneurol.2014.64

85. Menuet C, Connelly AA, Bassi JK, Melo MR, Le S, Kamar J, et al. PreBotzinger complex neurons drive respiratory modulation of blood pressure and heart rate. *Elife.* (2020) 9. doi: 10.7554/eLife.57288.sa2

86. Moridani MK, Farhadi H. Heart rate variability as a biomarker for epilepsy seizure prediction. *Bratisl Lek Listy.* (2017) 118:3-8. doi: 10.4149/BLL\_2017\_001

87. Hampel KG, Jahanbekam A, Elger CE, Surges R. Seizure-related modulation of systemic arterial blood pressure in focal epilepsy. *Epilepsia.* (2016) 57:1709–18. doi: 10.1111/epi.13504

88. Patodia S, Somani A, Thom M. Review: Neuropathology findings in autonomic brain regions in SUDEP and future research directions. *Auton Neurosci.* (2021) 235:102862. doi: 10.1016/j.autneu.2021.102862

89. Barot N, Nei M. Autonomic aspects of sudden unexpected death in epilepsy (SUDEP). *Clin Auton Res.* (2019) 29:151–60. doi: 10.1007/s10286-018-0576-1

90. van der Lende M, Surges R, Sander JW, Thijs RD. Cardiac arrhythmias during or after epileptic seizures. *J Neurol Neurosurg Psychiatry*. (2016) 87:69–74. doi: 10.1016/j.autneu.2015.07.066

91. Myers KA, Bello-Espinosa LE, Symonds JD, Zuberi SM, Clegg R, Sadleir LG, et al. Heart rate variability in epilepsy: a potential biomarker of sudden unexpected death in epilepsy risk. *Epilepsia*. (2018) 59:1372–80. doi: 10.1111/epi.14438

92. Sivathamboo S, Friedman D, Laze J, Nightscales R, Chen Z, Kuhlmann L, et al. Association of short-term heart rate variability and sudden unexpected death in epilepsy. *Neurology*. (2021) 97:e2357–67. doi: 10.1212/WNL.000000000012946

93. Englot DJ, Morgan VL, Chang C. Impaired vigilance networks in temporal lobe epilepsy: Mechanisms and clinical implications. *Epilepsia*. (2020) 61:189–202. doi: 10.1111/epi.16423

94. Buehler PK, Bleiler D, Tegtmeier I, Heitzmann D, Both C, Georgieff M, et al. Abnormal respiration under hyperoxia in TASK-1/3 potassium channel double knockout mice. *Respir Physiol Neurobiol.* (2017) 244:17–25. doi: 10.1016/j.resp.2017.06.009

95. Koch H, Zanella S, Elsen GE, Smith L, Doi A, Garcia AJ, et al. Stable respiratory activity requires both P/Q-type and N-type voltage-gated calcium channels. *J Neurosci.* (2013) 33:3633–45. doi: 10.1523/JNEUROSCI.6390-11.2013

96. Lu B, Su Y, Das S, Liu J, Xia J, Ren D, et al. The neuronal channel NALCN contributes resting sodium permeability and is required for normal respiratory rhythm. *Cell*. (2007) 129:371–83. doi: 10.1016/j.cell.2007.02.041

97. Quintana A, Zanella S, Koch H, Kruse SE, Lee D, Ramirez JM, et al. Fatal breathing dysfunction in a mouse model of Leigh syndrome. *J Clin Invest.* (2012) 122:2359–68. doi: 10.1172/JCI62923

98. Gallego J, Dauger S. PHOX2B mutations and ventilatory control. Respir Physiol Neurobiol. (2008) 164:49-54. doi: 10.1016/j.resp.2008.07.003

99. Ramirez JM, Doi A, Garcia AJ, Elsen FP, Koch H, Wei AD. The cellular building blocks of breathing. *Compr Physiol.* (2012) 2:2683–731. doi:10.1002/cphy.c110033

100. Murugesan A, Rani MRS, Hampson J, Zonjy B, Lacuey N, Faingold CL, et al. Serum serotonin levels in patients with epileptic seizures. *Epilepsia.* (2018) 59:e91–7. doi: 10.1111/epi.14198

101. Nass RD, Motloch LJ, Paar V, Lichtenauer M, Baumann J, Zur B, et al. Blood markers of cardiac stress after generalized convulsive seizures. *Epilepsia.* (2019) 60:201–10. doi: 10.1111/epi.14637

102. Simon RP, Aminhoff MJ, Benowitz NL. Changes in plasma catecholamines after tonic-clonic seizures. *Neurology*. (1984) 34:255–7. doi: 10.1212/WNL.34.2.255

103. Garcia AJ, Koschnitzky JE, Ramirez JM. The physiological determinants of sudden infant death syndrome. *Respir Physiol Neurobiol.* (2013) 189:288–300. doi: 10.1016/j.resp.2013.05.032

104. McCulloch K, Brouillette RT, Guzzetta AJ, Hunt CE. Arousal responses in near-miss sudden infant death syndrome and in normal infants. *J Pediatr.* (1982) 101:911–7. doi: 10.1016/S0022-3476(82)80009-7

105. Sawaguchi T, Kato I, Franco P, Sottiaux M, Kadhim H, Shimizu S, et al. Apnea, glial apoptosis and neuronal plasticity in the arousal pathway of victims of SIDS. *Forensic Sci Int.* (2005) 149:205–17. doi: 10.1016/j.forsciint.2004.10.015

106. Buchanan GF. Impaired CO2-induced arousal in SIDS and SUDEP. *Trends Neurosci.* (2019) 42:242–50. doi: 10.1016/j.tins.2019.02.002

107. Crandall LG, Lee JH, Stainman R, Friedman D, Devinsky O. Potential role of febrile seizures and other risk factors associated with sudden deaths in children. *JAMA Netw Open*. (2019) 2:e192739. doi: 10.1001/jamanetworkopen.2019.2739

108. Hesdorffer DC, Crandall LA, Friedman D, Devinsky O. Sudden unexplained death in childhood: A comparison of cases with and without a febrile seizure history. *Epilepsia*. (2015) 56:1294–300. doi: 10.1111/epi.13066

109. Richerson GB, Buchanan GF. The serotonin axis: Shared mechanisms in seizures, depression, and SUDEP. *Epilepsia.* (2011) 52:28–38. doi: 10.1111/j.1528-1167.2010.02908.x

110. Lijowska AS, Reed NW, Chiodini BA, Thach BT. Sequential arousal and airway-defensive behavior of infants in asphyxial sleep environments. *J Appl Physiol.* (1997) 83:219–28. doi: 10.1152/jappl.1997.83.1.219

111. McNamara F, Wulbrand H, Thach BT. Characteristics of the infant arousal response. J Appl Physiol. (1982) 85:2314–21. doi: 10.1152/jappl.1998.85.6.2314

112. Ramirez JM. The integrative role of the sigh in psychology, physiology, pathology, and neurobiology. *Prog Brain Res.* (2014) 209:91–129. doi: 10.1016/B978-0-444-63274-6.00006-0

113. Lieske SP, Thoby-Brisson M, Telgkamp P, Ramirez JM. Reconfiguration of the neural network controlling multiple breathing patterns: eupnea, sighs and gasps. *Nat Neurosci.* (2000) 3:600–7. doi: 10.1038/75776

114. Cassell MD, Freedman LJ, Shi C. The intrinsic organization of the central extended amygdala. *Ann N Y Acad Sci.* (1999) 877:217–41. doi: 10.1111/j.1749-6632.1999.tb09270.x

115. Dong HW, Swanson LW. Projections from bed nuclei of the stria terminalis, dorsomedial nucleus: implications for cerebral hemisphere integration of neuroendocrine, autonomic, and drinking responses. *J Comp Neurol.* (2006) 494:75–107. doi: 10.1002/cne.20790

116. Pollak Dorocic I, Furth D, Xuan Y, Johansson Y, Pozzi L, Silberberg G, et al. A whole-brain atlas of inputs to serotonergic neurons of the dorsal and median raphe nuclei. *Neuron.* (2014) 83:663–78. doi: 10.1016/j.neuron.2014.07.002

117. Reichard RA, Subramanian S, Desta MT, Sura T, Becker ML, Ghobadi CW, et al. Abundant collateralization of temporal lobe projections to the accumbens, bed nucleus of stria terminalis, central amygdala and lateral septum. *Brain Struct Funct.* (2017) 222:1971–88. doi: 10.1007/s00429-016-1321-y

118. Garcia AJ, Rotem-Kohavi N, Doi A, Ramirez JM. Post-hypoxic recovery of respiratory rhythm generation is gender dependent. *PLoS ONE.* (2013) 8:e60695. doi: 10.1371/journal.pone.0060695

119. Poets CF, Meny RG, Chobanian MR, Bobofiglo RE. Gasping and other cardiorespiratory patterns during sudden infant deaths. *Pediatr Res.* (1999) 45:350–4. doi: 10.1203/00006450-199903000-00010

120. Sintas C, Fernandez-Castillo N, Vila-Pueyo M, Pozo-Rosich P, Macaya A, Cormand B, et al. Transcriptomic changes in rat cortex and brainstem after cortical spreading depression with or without pretreatment with migraine prophylactic drugs. J Pain. (2017) 18:366–75. doi: 10.1016/j.jpain.2016.11.007

121. Paton JF, Abdala AP, Koizumi H, Smith JC, St-John WM. Respiratory rhythm generation during gasping depends on persistent sodium current. *Nat Neurosci.* (2006) 9:311–3. doi: 10.1038/nn1650

122. Telgkamp P, Ramirez JM. Differential responses of respiratory nuclei to anoxia in rhythmic brain stem slices of mice. *J Neurophysiol.* (1999) 82:2163–70. doi: 10.1152/jn.1999.82.5.2163

123. Schmidt C, Bellingham MC, Richter DW. Adenosinergic modulation of respiratory neurones and hypoxic responses in the anaesthetized cat. *J Physiol.* (1995) 483:769–81. doi: 10.1113/jphysiol.1995.sp020621

124. Koch H, Caughie C, Elsen FP, Doi A, Garcia AJ, Zanella S, Ramirez JM. Prostaglandin E2 differentially modulates the central control of eupnoea, sighs and gasping in mice. *J Physiol*. (2015) 593:305–19. doi: 10.1113/jphysiol.2014.279794

125. Pena F, Aguileta MA. Effects of riluzole and flufenamic acid on eupnea and gasping of neonatal mice *in vivo. Neurosci Lett.* (2007) 415:288–93. doi: 10.1016/j.neulet.2007.01.032

126. Pena F, Parkis MA, Tryba AK, Ramirez JM. Differential contribution of pacemaker properties to the generation of respiratory rhythms during normoxia and hypoxia. *Neuron.* (2004) 43:105–17. doi: 10.1016/j.neuron.2004.06.023

127. Layer N, Brandes J, Luhrs PJ, Wuttke TV, Koch H. The effect of lamotrigine and other antiepileptic drugs on respiratory rhythm generation in the pre-Botzinger complex. *Epilepsia*. (2021) 62:2790–803. doi: 10.1111/epi.17066

128. Christensen J, Trabjerg BB, Dreier JW. Cardiac morbidity and mortality associated with the use of lamotrigine. *Epilepsia.* (2022) 63:2371-80. doi: 10.1111/epi.17339

129. Zanella S, Doi A, Garcia AJ, Elsen F, Kirsch S, Wei AD, Ramirez JM. When norepinephrine becomes a driver of breathing irregularities: how intermittent hypoxia fundamentally alters the modulatory response of the respiratory network. *J Neurosci.* (2014) 34:36–50. doi: 10.1523/JNEUROSCI.3644-12.2014

130. Bruxel EM, Bruno DCF, Do Canto AM, Geraldis JC, Godoi AB, Martin M, et al. Multi-omics in mesial temporal lobe epilepsy with hippocampal sclerosis: Clues into the underlying mechanisms leading to disease. *Seizure.* (2021) 90:34–50. doi: 10.1016/j.seizure.2021.03.002

131. Grainger AI, King MC, Nagel DA, Parri HR, Coleman MD, Hill EJ, et al. *In vitro* models for seizure-liability testing using induced pluripotent stem cells. *Front Neurosci.* (2018) 12:590. doi: 10.3389/fnins.2018.00590

132. Raimondo JV, Heinemann U, Curtis D, Goodkin M, Dulla, HP, et al. Methodological standards for *in vitro* models of epilepsy and epileptic seizures. A TASK1-WG4 report of the AES/ILAE translational task force of the ILAE. *Epilepsia*. (2017) 58:40–52. doi: 10.1111/epi.13901

133. Ziobro JM, Deshpande LS, Delorenzo RJ. An organotypic hippocampal slice culture model of excitotoxic injury induced spontaneous recurrent epileptiform discharges. *Brain Res.* (2011) 1371:110–20. doi: 10.1016/j.brainres.2010.11.065

134. Baraban S. Emerging epilepsy models: insights from mice, flies, worms and fish. *Curr Opin Neurol.* (2007) 20:164–8. doi: 10.1097/WCO.0b013e328042bae0

135. Buchsbaum IY, Cappello S. Neuronal migration in the CNS during development and disease: insights from *in vivo* and *in vitro* models. *Development*. (2019) 146:163766. doi: 10.1242/dev.163766

136. Kandratavicius L, Balista PA, Lopes-Aguiar C, Ruggiero RN, Umeoka EH, Garcia-Cairasco N, et al. Animal models of epilepsy: use and limitations. *Neuropsychiatr Dis Treat.* (2014) 10:1693–705. doi: 10.2147/NDT.S50371

137. Opitz A, Falchier A, Linn GS, Milham MP, Schroeder CE. Limitations of ex vivo measurements for *in vivo* neuroscience. *Proc Natl Acad Sci U S A*. (2017) 114:5243–6. doi: 10.1073/pnas.1617024114

138. Stewart AM, Braubach O, Spitsbergen J, Gerlai R, Kalueff AV. Zebrafish models for translational neuroscience research: from tank to bedside. *Trends Neurosci.* (2014) 37:264–78. doi: 10.1016/j.tins.2014.02.011

139. Schwarzacher SW, Rub U, Deller T. Neuroanatomical characteristics of the human pre-Botzinger complex and its involvement in neurodegenerative brainstem diseases. *Brain*. (2011) 134:24–35. doi: 10.1093/brain/awq327

140. Bentley JN, Chestek C, Stacey WC, Patil PG. Optogenetics in epilepsy. *Neurosurg Focus.* (2013) 34:E4. doi: 10.3171/2013.3.FOCUS1364

141. Helbig I, Ellis CA. Personalized medicine in genetic epilepsies - possibilities, challenges, and new frontiers. *Neuropharmacology.* (2020) 172:107970. doi: 10.1016/j.neuropharm.2020.107970

142. Helbig I, Tayoun AA. Understanding Genotypes and Phenotypes in Epileptic Encephalopathies. *Mol Syndromol.* (2016) 7:172–81. doi: 10.1159/000448530

143. Han K, Holder JL, Schaaf CP, Lu H, Chen H, Kang H, et al. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. *Nature*. (2013) 503:72–7. doi: 10.1038/nature12630

144. Jin C, Zhang Y, Kim S, Kim Y, Lee Y, Han K, et al. Spontaneous seizure and partial lethality of juvenile Shank3-overexpressing mice in C57BL/6 J background. *Mol Brain.* (2018) 11:57. doi: 10.1186/s13041-018-0403-6

145. Lee Y, Zhang Y, Kim S, Han K. Excitatory and inhibitory synaptic dysfunction in mania: an emerging hypothesis from animal model studies. *Exp Mol Med.* (2018) 50:1–11. doi: 10.1038/s12276-018-0187-x

146. Lewis ML, Kesler M, Candy SA, Rho JM, Pittman QJ. Comorbid epilepsy in autism spectrum disorder: Implications of postnatal inflammation for brain excitability. *Epilepsia*. (2018) 59:1316–26. doi: 10.1111/epi.14440

147. Seiffert S, Pendziwiat M, Bierhals T, Goel H, Schwarz N, van der Ven A, et al. Modulating effects of FGF12 variants on NaV1.2 and NaV1.6 being associated with developmental and epileptic encephalopathy and Autism spectrum disorder: a case series. *EBioMedicine*. (2022) 83:104234. doi: 10.1016/j.ebiom.2022.104234

148. Wong JC, Grieco SF, Dutt K, Chen L, Thelin JT, Inglis GAS, et al. Autistic-like behavior, spontaneous seizures, and increased neuronal excitability in a Scn8a mouse model. *Neuropsychopharmacology*. (2021) 46:2011–20. doi: 10.1038/s41386-021-00985-9

149. Guerrini R, Conti V, Mantegazza M, Balestrini S, Galanopoulou AS, Benfenati F, et al. Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum. *Physiol Rev.* (2023) 103:433–513. doi: 10.1152/physrev.00063.2021

150. Colmers PLW, Maguire J. Network dysfunction in comorbid psychiatric illnesses and epilepsy. *Epilepsy Curr.* (2020) 20:205–10. doi: 10.1177/1535759720934787

151. Weston CSE. Four Social Brain Regions, Their Dysfunctions, and Sequelae, Extensively Explain Autism Spectrum Disorder Symptomatology. *Brain Sci.* (2019) 9:130. doi: 10.3390/brainsci9060130

152. Marshall GF, Gonzalez-Sulser A, Abbott CM. Modelling epilepsy in the mouse: challenges and solutions. *Dis Model Mech.* (2021) 14:47449. doi: 10.1242/dmm.047449

153. Di Sapia R, Moro F, Montanarella M, Iori V, Micotti E, Tolomeo D, et al. In-depth characterization of a mouse model of post-traumatic epilepsy for biomarker and drug discovery. *Acta Neuropathol Commun.* (2021) 9:76. doi: 10.1186/s40478-021-01165-y

154. Meisler MH, Kearney J, Escayg A, MacDonald BT, Sprunger LK. Sodium channels and neurological disease: insights from Scn8a mutations in the mouse. *Neuroscientist.* (2001) 7:136–45. doi: 10.1177/107385840100700208

155. Goldman AM, Buchanan G, Aiba I, Noebels JL. SUDEP Animal Models. *Models Seizures Epilepsy.* (2017) 1:1007–18. doi: 10.1016/B978-0-12-804066-9.00070-5 156. Catterall WA. Sodium Channel Mutations and Epilepsy in Jasper's Basic Mechanisms of the Epilepsies. Bethesda, MD: National Center for Biotechnology Information (2012).

157. Mantegazza M, Cestele S, Catterall WA. Sodium channelopathies of skeletal muscle and brain. *Physiol Rev.* (2021) 101:1633-89. doi: 10.1152/physrev.00025.2020

158. Meisler MH, Hill SF, Yu W. Sodium channelopathies in neurodevelopmental disorders. *Nat Rev Neurosci.* (2021) 22:152–66. doi: 10.1038/s41583-020-00418-4

159. Glasscock E, Yoo JW, Chen TT, Klassen TL, Noebels JL. Kv1.1 potassium channel deficiency reveals brain-driven cardiac dysfunction as a candidate mechanism for sudden unexplained death in epilepsy. *J Neurosci.* (2010) 30:5167–75. doi: 10.1523/JNEUROSCI.5591-09.2010

160. Smart SL, Lopantsev V, Zhang CL, Robbins CA, Wang H, Chiu SY, et al. Deletion of the KV1.1 potassium channel causes epilepsy in mice. *Neuron.* (1998) 20:809–19. doi: 10.1016/S0896-6273(00)81018-1

161. Felix R. Insights from mouse models of absence epilepsy into Ca<sup>2+</sup> channel physiology and disease etiology. *Cell Mol Neurobiol.* (2002) 22:103–20. doi: 10.1023/A:1019807719343

162. Goldman AM, Glasscock E, Yoo J, Chen TT, Klassen TL, Noebels JL, et al. Arrhythmia in heart and brain: KCNQ1 mutations link epilepsy and sudden unexplained death. *Sci Transl Med.* (2009) 1:6. doi: 10.1126/scitranslmed.3000289

163. Yuan Y, O'Malley HA, Smaldino MA, Bouza AA, Hull JM, Isom LL, et al. Delayed maturation of GABAergic signaling in the Scn1a and Scn1b mouse models of Dravet Syndrome. *Sci Rep.* (2019) 9:6210. doi: 10.1038/s41598-019-42191-0

164. Wengert ER, Wenker IC, Wagner EL, Wagley PK, Gaykema RP, Shin JB, et al. Adrenergic mechanisms of audiogenic seizure-induced death in a mouse model of SCN8A encephalopathy. *Front Neurosci.* (2021) 15:581048. doi:10.3389/fnins.2021.581048

165. Zamorano-Leon JJ, Yanez R, Jaime G, Rodriguez-Sierra P, Calatrava-Ledrado L, Alvarez-Granada RR, et al. KCNH2 gene mutation: a potential link between epilepsy and long QT-2 syndrome. *J Neurogenet*. (2012) 26:382–6. doi: 10.3109/01677063.2012.674993

166. Auerbach DS, Jones J, Clawson BC, Offord J, Lenk GM, Ogiwara I, et al. Altered cardiac electrophysiology and SUDEP in a model of Dravet syndrome. *PLoS One.* (2013) 8:e77843. doi: 10.1371/journal.pone.0077843

167. Brunklaus A, Zuberi SM. Dravet syndrome-from epileptic encephalopathy to channelopathy. *Epilepsia*. (2014) 55:979-84. doi: 10.1111/epi.12652

168. Connolly MB. Dravet syndrome: diagnosis and long-term course. Can J Neurol Sci. (2016) 43:S3-8. doi: 10.1017/cjn.2016.243

169. Kim Y, Bravo E, Thirnbeck CK, Smith-Mellecker LA, Kim SH, Gehlbach BK, et al. Severe peri-ictal respiratory dysfunction is common in Dravet syndrome. *J Clin Invest.* (2018) 128:1141–53. doi: 10.1172/JCI94999

170. Hedrich UB, Liautard C, Kirschenbaum D, Pofahl M, Lavigne J, Liu Y, et al. Impaired action potential initiation in GABAergic interneurons causes hyperexcitable networks in an epileptic mouse model carrying a human Na(V)1.1 mutation. *J Neurosci.* (2014) 34:14874–89. doi: 10.1523/JNEUROSCI.0721-14.2014

171. Layer N, Sonnenberg L, Pardo Gonzalez E, Benda J, Hedrich UBS, Lerche H, et al. Dravet Variant SCN1A (A1783V) Impairs Interneuron Firing Predominantly by Altered Channel Activation. *Front Cell Neurosci.* (2021) 15:754530. doi: 10.3389/fncel.2021.754530

172. Tran CH, Vaiana M, Nakuci J, Somarowthu A, Goff KM, Goldstein N, et al. Interneuron desynchronization precedes seizures in a mouse model of dravet syndrome. *J Neurosci.* (2020) 40:2764–75. doi: 10.1523/JNEUROSCI.2370-19.2020

173. Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. *Nat Neurosci.* (2006) 9:1142–9. doi: 10.1038/nn1754

174. Lange, d. e., Gunning, I. M., Sonsma, B., van Gemert, A. C. M., van Kempen, L., Verbeek, M., et al. (2019). Outcomes and comorbidities of SCN1A-related seizure disorders. *Epilepsy Behav* 90, 252–259. doi: 10.1016/j.yebeh.2018.09.041

175. Studtmann C, Ladislav M, Topolski MA, Safari M, Swanger SA. NaV1.1 haploinsufficiency impairs glutamatergic and GABAergic neuron function in the thalamus. *Neurobiol Dis.* (2022) 167:105672. doi: 10.1016/j.nbd.2022.105672

176. Cheah CS, Yu FH, Westenbroek RE, Kalume FK, Oakley JC, Potter GB, et al. Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. *Proc Natl Acad Sci U S A.* (2012) 109:14646–51. doi: 10.1073/pnas.12115 91109

177. Gataullina S, Dulac O. From genotype to phenotype in Dravet disease. Seizure. (2017) 44:58–64. doi: 10.1016/j.seizure.2016.10.014

178. Han S, Tai C, Westenbroek RE, Yu FH, Cheah CS, Potter GB, et al. Autistic-like behaviour in Scn1a+/- mice and rescue by enhanced GABA-mediated neurotransmission. *Nature*. (2012) 489:385–90. doi: 10.1038/nature11356

179. Kuo FS, Cleary CM, LoTurco JJ, Chen X, Mulkey DK. Disordered breathing in a mouse model of Dravet syndrome. *Elife.* (2019) 8:22. doi: 10.7554/eLife.43387.022

180. Ricobaraza A, Mora-Jimenez L, Puerta E, Sanchez-Carpintero R, Mingorance A, Artieda J, et al. Epilepsy and neuropsychiatric comorbidities in mice carrying a recurrent Dravet syndrome SCN1A missense mutation. *Sci Rep.* (2019) 9:14172. doi: 10.1038/s41598-019-50627-w

181. Chen C, Westenbroek RE, Xu X, Edwards CA, Sorenson DR, Chen Y, et al. Mice lacking sodium channel beta1 subunits display defects in neuronal excitability, sodium channel expression, and nodal architecture. *J Neurosci.* (2004) 24:4030–42. doi: 10.1523/JNEUROSCI.4139-03.2004

182. Wenker IC, Blizzard EA, Wagley PK, Patel MK. Peri-ictal autonomic control of cardiac function and seizure-induced death. *Front Neurosci.* (2021) 15:795145. doi: 10.3389/fnins.2021.795145

183. Dhaibar H, Gautier NM, Chernyshev OY, Dominic P, Glasscock E. Cardiorespiratory profiling reveals primary breathing dysfunction in Kcna1-null mice: Implications for sudden unexpected death in epilepsy. *Neurobiol Dis.* (2019) 127:502–11. doi: 10.1016/j.nbd.2019.04.006

184. Guan D, Lee JC, Higgs MH, Spain WJ, Foehring RC. Functional roles of Kv1 channels in neocortical pyramidal neurons. *J Neurophysiol*. (2007) 97:1931–40. doi: 10.1152/jn.00933.2006

185. Wang H, Kunkel DD, Schwartzkroin PA, Tempel BL. Localization of Kv1.1 and Kv1.2. Two K channel proteins, to synaptic terminals, somata, and dendrites in the mouse brain. *J Neurosci.* (1994) 14:4588–99. doi:10.1523/JNEUROSCI.14-08-04588.1994

186. Moore BM, Jerry Jou C, Tatalovic M, Kaufman ES, Kline DD, Kunze DL, et al. The Kv1.1 null mouse a model of sudden unexpected death in epilepsy (SUDEP). *Epilepsia*. (2014) 55:1808–16. doi: 10.1111/epi.12793

187. Simeone KA, Hallgren J, Bockman CS, Aggarwal A, Kansal V, Netzel L, et al. Respiratory dysfunction progresses with age in Kcna1-null mice, a model of sudden unexpected death in epilepsy. *Epilepsia*. (2018) 59:345–57. doi: 10.1111/epi.13971

188. Thouta S, Zhang Y, Garcia E, Snutch TP. Kv1.1 channels mediate network excitability and feed-forward inhibition in local amygdala circuits. *Sci Rep.* (2021) 11:15180. doi: 10.1038/s41598-021-94633-3

189. Partemi S, Cestele S, Pezzella M, Campuzano O, Paravidino R, Pascali VL, et al. Loss-of-function KCNH2 mutation in a family with long QT syndrome, epilepsy, and sudden death. *Epilepsia*. (2013) 54:e112–116. doi: 10.1111/epi.12259

190. Tiron C, Campuzano O, Perez-Serra A, Mademont I, Coll M, Allegue C, et al. Further evidence of the association between LQT syndrome and epilepsy in a family with KCNQ1 pathogenic variant. *Seizure*. (2015) 25:65–7. doi: 10.1016/j.seizure.2015.01.003

191. Hawkins NA, Anderson LL, Gertler TS, Laux L, George AL, Kearney JA. Screening of conventional anticonvulsants in a genetic mouse model of epilepsy. *Ann Clin Transl Neurol.* (2017) 4:326–39. doi: 10.1002/acn3.413

192. Chauvette S, Soltani S, Seigneur J, Timofeev I. *In vivo* models of cortical acquired epilepsy. *J Neurosci Methods.* (2016) 260:185–201. doi: 10.1016/j.jneumeth.2015.08.030

193. Rubio C, Rubio-Osornio M, Retana-Marquez S, Veronica Custodio ML, Paz C. *In vivo* experimental models of epilepsy. *Cent Nerv Syst Agents Med Chem.* (2010) 10:298–309. doi: 10.2174/187152410793429746

194. Ortiz C, Carlen M, Meletis K. Spatial transcriptomics: molecular maps of the mammalian brain. *Annu Rev Neurosci.* (2021) 44:547-62. doi: 10.1146/annurev-neuro-100520-082639

195. Boyden E. Optogenetics and the future of neuroscience. Nat. Neurosci. (2015) 18;1200-1. doi: 10.1038/nn.4094

196. Shimoda Y, Beppu K, Ikoma Y, Morizawa YM, Zuguchi S, Hino U, et al. Optogenetic stimulus-triggered acquisition of seizure resistance. *Neurobiol Dis.* (2022) 163:105602. doi: 10.1016/j.nbd.2021.105602

197. Mahmoudi P, Veladi H, Pakdel F. Optogenetics, tools and applications in neurobiology. J Med Signals Sens. (2017) 7:71–9. doi: 10.4103/2228-7477.205506

198. Pouliopoulos AN, Murillo MF, Noel RL, Batts AJ, Ji R, Kwon N, et al. Non-invasive optogenetics with ultrasound-mediated gene delivery and red-light excitation. *Brain Stimul.* (2022) 15:927–41. doi: 10.1016/j.brs.2022.06.007

199. Campbell EJ, Marchant NJ. The use of chemogenetics in behavioural neuroscience: receptor variants, targeting approaches and caveats. *Br J Pharmacol.* (2018) 175:994–1003. doi: 10.1111/bph.14146

200. Berglund K, Tung JK, Higashikubo B, Gross RE, Moore CI, Hochgeschwender U, et al. Combined optogenetic and chemogenetic

control of neurons. *Methods Mol Biol.* (2016) 1408:207-25. doi: 10.1007/978-1-4939-3512-3\_14

201. Cela E, Sjöström PJ. Novel optogenetic approaches in epilepsy research. Front Neurosci. (2019) 13:947. doi: 10.3389/fnins.2019.00947

202. Staba RJ, Stead M, Worrell GA. Electrophysiological biomarkers of epilepsy. Neurotherapeutics. (2014) 11:334-46. doi: 10.1007/s13311-014-0259-0

203. Choi JH, Koch KP, Poppendieck W, Lee M, Shin HS. High resolution electroencephalography in freely moving mice. *J Neurophysiol.* (2010) 104:1825–34. doi: 10.1152/jn.00188.2010

204. Sheybani L, Birot G, Contestabile A, Seeck M, Kiss JZ, Schaller K, et al. Electrophysiological evidence for the development of a self-sustained large-scale epileptic network in the kainate mouse model of temporal lobe epilepsy. *J Neurosci.* (2018) 38:3776–91. doi: 10.1523/JNEUROSCI.2193-17.2018

205. Dai Y, Song Y, Xie J, Xu S, Li X, He E, et al. *In vivo* microelectrode arrays for detecting multi-region epileptic activities in the hippocampus in the latent period of rat model of temporal lobe epilepsy. *Micromachines.* (2021) 12:6. doi: 10.3390/mi12060659

206. Houben T, Loonen IC, Baca SM, Schenke M, Meijer JH, Ferrari MD, et al. Optogenetic induction of cortical spreading depression in anesthetized and freely behaving mice. *J Cereb Blood Flow Metab.* (2017) 37:1641–55. doi: 10.1177/0271678X16645113

207. Chung DY, Sugimoto K, Fischer P, Bohm M, Takizawa T, Sadeghian H, et al. Real-time non-invasive *in vivo* visible light detection of cortical spreading depolarizations in mice. *J Neurosci Methods*. (2018) 309:143–6. doi: 10.1016/j.jneumeth.2018.09.001

208. Smith JM, Bradley DP, James MF, Huang CL. Physiological studies of cortical spreading depression. *Biol Rev Camb Philos Soc.* (2006) 81:457–81. doi: 10.1017/S1464793106007081

209. Dufour S, Koninck Y. Optrodes for combined optogenetics and electrophysiology in live animals. *Neurophotonics*. (2015) 2:1-14. doi: 10.1117/1.NPh.2.3.031205

210. Tian H, Xu K, Zou L, Fang Y. Multimodal neural probes for combined optogenetics and electrophysiology. *iScience*. (2022) 25:103612. doi: 10.1016/j.isci.2021.103612

211. Anikeeva P, Andalman AS, Witten I, Warden M, Goshen I, Grosenick L, et al. Optetrode: a multichannel readout for optogenetic control in freely moving mice. *Nat Neurosci.* (2011) 15:163–70. doi: 10.1038/nn.2992

212. Lu Y, Zhong C, Wang L, Wei P, He W, Huang K, et al. Optogenetic dissection of ictal propagation in the hippocampal-entorhinal cortex structures. *Nat Commun.* (2016) 7:10962. doi: 10.1038/ncomms10962

213. Lim DH, Ledue J, Mohajerani MH, Vanni MP, Murphy TH. Optogenetic approaches for functional mouse brain mapping. *Front Neurosci.* (2013) 7:54. doi: 10.3389/fnins.2013.00054

214. Xiao D, Forys BJ, Vanni MP, Murphy TH. MesoNet allows automated scaling and segmentation of mouse mesoscale cortical maps using machine learning. *Nat Commun.* (2021) 12:5992. doi: 10.1038/s41467-021-26255-2

215. Fehervari TD, Okazaki Y, Sawai H, Yagi T. *In vivo* voltage-sensitive dye study of lateral spreading of cortical activity in mouse primary visual cortex induced by a current impulse. *PLoS ONE.* (2015) 10:e0133853. doi: 10.1371/journal.pone.0133853

216. Goldberg EM, Coulter DA. Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction. *Nat Rev Neurosci.* (2013) 14:337–49. doi: 10.1038/nrn3482

217. Oh J, Lee C, Kaang BK. Imaging and analysis of genetically encoded calcium indicators linking neural circuits and behaviors. *Korean J Physiol Pharmacol.* (2019) 23:237–49. doi: 10.4196/kjpp.2019.23.4.237

218. Somarowthu A, Goff KM, Goldberg EM. Two-photon calcium imaging of seizures in awake, head-fixed mice. *Cell Calcium.* (2021) 96:102380. doi: 10.1016/j.ceca.2021.102380

219. Li L, Tang Y, Sun L, Rahman K, Huang K, Xu W, et al. *In vivo* fiber photometry of neural activity in response to optogenetically manipulated inputs in freely moving mice. *J Innov Opt Health Sci.* (2017) 10:5. doi: 10.1142/S1793545817430015

220. Dong X, Zhang X, Wang F, Liu N, Liu A, Li Y, et al. Simultaneous calcium recordings of hippocampal CA1 and primary motor cortex M1 and their relations to behavioral activities in freely moving epileptic mice. *Exp Brain Res.* (2020) 238:1479–88. doi: 10.1007/s00221-020-05 815-w

221. Patel AA, McAlinden N, Mathieson K, Sakata S. Simultaneous electrophysiology and fiber photometry in freely behaving mice. *Front Neurosci.* (2020) 14:148. doi: 10.3389/fnins.2020.00148

222. Levesque M, Wang S, Etter G, Williams S, Avoli M. Bilateral optogenetic activation of inhibitory cells favors ictogenesis. *Neurobiol Dis.* (2022) 171:105794. doi: 10.1016/j.nbd.2022.105794

223. Furman M, Zhan Q, McCafferty C, Lerner BA, Motelow JE, Meng J, et al. Optogenetic stimulation of cholinergic brainstem neurons during focal limbic seizures: Effects on cortical physiology. *Epilepsia.* (2015) 56:e198–202. doi: 10.1111/epi.13220

224. Liu S, Han S. Simultaneous recording of breathing and neural activity in awake behaving mice. *STAR Protoc.* (2022) 3:101412. doi: 10.1016/j.xpro.2022.101412

225. Ho D, Zhao X, Gao S, Hong C, Vatner DE, Vatner SF, et al. Heart rate and electrocardiography monitoring in mice. *Curr Protoc Mouse Biol.* (2011) 1:123–39. doi: 10.1002/9780470942390.mo100159

226. Mongue-Din H, Salmon A, Fiszman MY, Fromes Y. Non-invasive restrained ECG recording in conscious small rodents: a new tool for cardiac electrical activity investigation. *Pflugers Arch.* (2007) 454:165–71. doi: 10.1007/s00424-006-0197-8

227. Grimaud J, Murthy VN. How to monitor breathing in laboratory rodents: a review of the current methods. *J Neurophysiol.* (2018) 120:624–32. doi: 10.1152/jn.00708.2017

228. Viemari JC, Roux JC, Tryba AK, Saywell V, Burnet H, Pena F, et al. Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. *J Neurosci.* (2005) 25:11521–30. doi: 10.1523/JNEUROSCI.4373-05.2005

229. Park KJ, Sharma G, Kennedy JD, Seyal M. Potentially high-risk cardiac arrhythmias with focal to bilateral tonic-clonic seizures and generalized tonic-clonic seizures are associated with the duration of periictal hypoxemia. *Epilepsia*. (2017) 58:2164–71. doi: 10.1111/epi.13934

230. Medinaceli Quintela R, Bauer J, Wallhorn L, Le K, Brunert D, Rothermel M, et al. Dynamic impairment of olfactory behavior and signaling mediated by an olfactory corticofugal system. *J Neurosci.* (2020) 40:7269–85. doi: 10.1523/JNEUROSCI.2667-19.2020

231. Kaneko K, Currin CB, Goff KM, Wengert ER, Somarowthu A, Vogels TP, et al. Developmentally regulated impairment of parvalbumin interneuron synaptic transmission in an experimental model of Dravet syndrome. *Cell Rep.* (2022) 38:110580. doi: 10.1016/j.celrep.2022.110580

232. Valassina N, Brusco S, Salamone A, Serra L, Luoni M, Giannelli S, et al. Scn1a gene reactivation after symptom onset rescues pathological phenotypes in a mouse model of Dravet syndrome. *Nat Commun.* (2022) 13:161. doi: 10.1038/s41467-021-27837-w

233. Lein E, Borm LE, Linnarsson S. The promise of spatial transcriptomics for neuroscience in the era of molecular cell typing. *Science*. (2017) 358:64–9. doi: 10.1126/science.aan6827

234. Leitner DF, Mills JD, Pires G, Faustin A, Drummond E, Kanshin E, et al. Proteomics and Transcriptomics of the hippocampus and cortex in SUDEP and high-risk SUDEP Patients. *Neurology.* (2021) 96:e2639–52. doi: 10.1212/WNL.000000000011999

235. Hutson TN, Rezaei F, Gautier NM, Indumathy J, Glasscock E, Iasemidis L, et al. Directed Connectivity Analysis of the Neuro-Cardio- and Respiratory

Systems Reveals Novel Biomarkers of Susceptibility to SUDEP. IEEE Open J Eng Med Biol. (2020) 1:301–11. doi: 10.1109/OJEMB.2020.3036544

236. Boon P, Raedt R, Herdt DE, Wyckhuys VT, Vonck K. Electrical stimulation for the treatment of epilepsy. *Neurotherapeutics*. (2009) 6:218–27. doi: 10.1016/j.nurt.2008.12.003

237. Chaitanya G, Hampson JP, Toth E, Hupp NJ, Hampson JS, Mosher JC, et al. Limbic and paralimbic respiratory modulation: from inhibition to enhancement. *Epilepsia*. (2022) 63:1799–811. doi: 10.1111/epi.17244

238. Zhang H, Zhao H, Zeng C, Van Dort C, Faingold CL, Taylor NE, et al. Optogenetic activation of 5-HT neurons in the dorsal raphe suppresses seizureinduced respiratory arrest and produces anticonvulsant effect in the DBA/1 mouse SUDEP model. *Neurobiol Dis.* (2018) 110:47–58. doi: 10.1016/j.nbd.2017.11.003

239. Magalhaes DM, Pereira N, Rombo DM, Beltrao-Cavacas C, Sebastiao AM, Valente CA, et al. Ex vivo model of epilepsy in organotypic slicesa new tool for drug screening. *J Neuroinflammation*. (2018) 15:203. doi: 10.1186/s12974-018-1225-2

240. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. *JAMA Neurol.* (2018) 75:279-86. doi: 10.1001/jamaneurol.2017.3949

241. Luoni C, Bisulli F, Canevini MP, Sarro D, Fattore G, et al. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. *Epilepsia*. (2011) 52:2181–91. doi: 10.1111/j.1528-1167.2011.03325.x

242. Ortinski P, Meador KJ. Cognitive side effects of antiepileptic drugs. *Epilepsy Behav.* (2004) 5:S60–65. doi: 10.1016/j.yebeh.2003.11.008

243. Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. *European Journal of Epilepsy.* (2011) 20:359–68. doi: 10.1016/j.seizure.2011.01.003

244. Engel J, Pitkanen A, Loeb JA, Dudek FE, Bertram EH, Cole AJ, et al. Epilepsy biomarkers. *Epilepsia*. (2013) 54:61–9. doi: 10.1111/epi.12299

245. Panuccio G, Colombi I, Chiappalone M. Recording and modulation of epileptiform activity in rodent brain slices coupled to microelectrode arrays. *J Vis Exp.* (2018) 135:57548. doi: 10.3791/57548

246. Ben-Menachem E. Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol. (2002) 1:477-82. doi: 10.1016/S1474-4422(02)00220-X

247. Han CL, Hu W, Stead M, Zhang T, Zhang JG, Worrell GA, et al. Electrical stimulation of hippocampus for the treatment of refractory temporal lobe epilepsy. *Brain Res Bull.* (2014) 109:13–21. doi: 10.1016/j.brainresbull.2014.08.007

248. Rodenkirch C, Carmel JB, Wang Q. Rapid effects of vagus nerve stimulation on sensory processing through activation of neuromodulatory systems. *Front Neurosci.* (2022) 16:922424. doi: 10.3389/fnins.2022.922424

249. Batson S, Shankar R, Conry J, Boggs J, Radtke R, Mitchell S, et al. Efficacy and safety of VNS therapy or continued medication management for treatment of adults with drug-resistant epilepsy: systematic review and meta-analysis. *J Neurol.* (2022) 269:2874–91. doi: 10.1007/s00415-022-10967-6